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Bacterial ATP-binding cassette (ABC) importers play
critical roles in nutrient acquisition and are potential
antibacterial targets. However, structural bases for
their inhibition are poorly defined. These pathways
typically rely on substrate binding proteins (SBPs),
which are essential for substrate recognition, deliv-
ery, and transporter function. We report the crystal
structure of a Staphylococcus aureus SBP for Mn(II),
termed MntC, in complex with FabC1, a potent anti-
body inhibitor of the MntABC pathway. This pathway
is essential and highly expressed during S. aureus
infection and facilitates the import of Mn(II), a critical
cofactor for enzymes that detoxify reactive oxygen
species (ROS). Structure-based functional studies
indicate that FabC1 sterically blocks a structurally
conserved surface of MntC, preventing its interaction
with the MntB membrane importer and increasing
wild-type S. aureus sensitivity to oxidative stress by
more than 10-fold. The results define anSBPblocking
mechanism as the basis for ABC importer inhibition
by an engineered antibody fragment.
INTRODUCTION
Pathogenic bacterial infections, such as those from Staphylo-
coccus aureus, are a leading cause of life-threatening human
diseases, including pneumonia, meningitis, and osteomyelitis
(Ippolito et al., 2010). Some strains have proven remarkably
successful at overcoming almost all host immune and antibiotic
strategies, thereby limiting therapeutic options (Gordon and
Lowy, 2008; Tice and Rehm, 2010). In particular, infections of
S. aureus that are resistant to vancomycin or multiantibiotic stra-
tegies are now endemic in many health care institutions and
communities (Cataldo et al., 2010; Ippolito et al., 2010; Murray,
2000), and there is a need to explore new therapeutic strategies.
Numerous factors contribute to the infectious capacity of path-
ogenic bacteria, including the production of specialized virulence
factors that are involved in nutrient acquisition (Cassat andStructure 23Skaar, 2012; Henderson and Martin, 2011; Rooijakkers et al.,
2005; Thurlow et al., 2012). For example, S. aureus expresses
various proteins that function to acquire nutrients from the host
environment, such as intramembrane ATP-binding cassette
(ABC) importers (Corbin et al., 2008; Schmaler et al., 2010;
Weinberg, 2009). These comprise a cytoplasmic ATPase, a
membrane permease, and an extracytoplasmic substrate bind-
ing protein (SBP), which binds substrate with high affinity and
critically couples substrate transport to ATPhydrolysis (Davidson
et al., 2008). Accordingly, SBPs perform the first essential step
in nutrient transport: substrate recognition and delivery to the
membrane importer.
S. aureus has evolved a robust and high-affinity ABC importer
pathway for Mn(II), termed MntABC (Horsburgh et al., 2002a).
Mn(II) acquisition is essential because it is a cofactor for super-
oxide dismutases and other proteins that neutralize reactive
oxygen species (ROS) produced during host oxidative burst
(Nauseef, 2004) and other intracellular redox reactions (Gaupp
et al., 2012; Imlay, 2003; Karavolos et al., 2003). Mn(II) is also a
critical cofactor for the nonenzymatic detoxification of ROS
(Horsburgh et al., 2002b) and other bacterial processes (Kehres
and Maguire, 2003). The MntABC importer uses a membrane-
anchored SBP, MntC, to chelate Mn(II) from the host environ-
ment and present it to the integral membrane transporter,
MntB. MntC expression is highly upregulated during infection,
and immunization of mice with purified MntC protein can lead
to the production of antibodies that confer some protective
immunity (Anderson et al., 2012a, 2012b; Brady et al., 2006).
All components of the MntABC pathway are essential for
S. aureus virulence in vivo (Diep et al., 2014) and mutant strains
also display increased sensitivity to ROS conditions in vitro
(Horsburgh et al., 2002a; Kehl-Fie et al., 2013), providing a
readily assayed phenotype for inhibition of Mn(II) import.
Antagonism of nutrient acquisition through ABC transporters
is a viable antibiotic strategy; however, molecular descriptions
of inhibitors of these pathways are scarce. In this study, we set
out to define new mechanisms to inhibit these nutrient acquisi-
tion pathways by attempting to use phage display technology
(Fellouse et al., 2007; Tonikian et al., 2007) to engineer and struc-
turally characterize an antibody fragment (Fab) that impedes
import. Recognizing the critical role SBPs play in substrate
recognition and delivery, we hypothesized that the S. aureus
MntABC transporter pathway could be selectively antagonized, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 713
Figure 1. Biochemical Analysis of the
MntC-FabC1 Complex
(A) Representative SEC data and corresponding
SDS-PAGE analysis showing Zn(II)-MntC-FabC1
complex formation. MW, molecular weight.
(B) Biolayer interferometry data of FabC1 binding
to Zn(II)-MntC, Mn(II)-MntC, and apo-MntC.
Shown are the saturation association (left of
dotted line) and dissociation (right of dotted line)
curves in which response (nm) was plotted as a
function of varying concentrations of FabC1:
2,000 nM (blue), 1,000 nM (red), 500 nM (light
blue), 250 nM (green), 125 nM (yellow), 62.5 nM
(purple), 31.3 nM (aqua-green), and 15.6 nM
(orange). Shown is a single representative data set
for each analysis. The reported KD values are the
average of three separate determinations and the
error reported is the SD.
(C) FabC1 binds cell-surface MntC: Flow cytom-
etery analysis of WT S. aureus, mntC null mutant,
and mntC null/tagO mutant strains (all strains
spa-). Shown are the percentage of cells present in
the Alexi Fluor 488 positive gate per 100K cells
counted.with an antibody fragment targeting its extracytoplasmic SBP,
thereby blocking Mn(II) import and sensitizing the bacteria to
oxidative stress. In the absence of a high-resolution structure
of the full MntABC complex, the Fab also served as a molecular
tool to probe the interaction interface of MntC with the MntB
transporter, as well as conformational changes that accompany
metal ion release. The structural, biochemical, and cellular re-
sults provide detailed molecular insight into a mechanism
to antagonize bacterial nutrient acquisition through ABC
transporters by targeting their SBPs with engineered antibody
therapeutics.
RESULTS
Generation of an Antibody Targeting an S. aureus
ABC Transporter Pathway
The feasibility of blocking an S. aureus ABC transporter with
an engineered antibody fragment was explored by targeting
MntC, a surface-associated virulence factor that plays an essen-
tial role in S. aureus infection by facilitating the acquisition of
Mn(II) from the host environment (Anderson et al., 2012a,
2012b; Brady et al., 2006; Diep et al., 2014). Loss or reduction
of MntC activity sensitizes S. aureus to oxidative stress, thereby
providing a quantifiable cellular phenotype for inhibition of this
ABC importer pathway. Using recombinant MntC as antigen,
an anti-MntC antibody fragment (Fab) was identified by phage
display methodology, termed FabC1. FabC1 formed a complex
with MntC in vitro that could be resolved by size exclusion chro-
matography (SEC) (Figure 1A). Biolayer interferometry experi-
ments indicated that FabC1 bound apo and metal-bound forms
of MntC with similar affinity (Figure 1B).
The specificity of FabC1 for MntC was further assessed by
examining its binding to MntC on live S. aureus cells. Cell wall-
associated protein A binds the Fcg fragment of IgG and also
has some affinity for the Fab fragment of VH3 antibodies (Hillson714 Structure 23, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rightset al., 1993); FabC1 is derived from a VH3 library. Therefore, to
reduce nonspecific binding to cells in these experiments, we
eliminated endogenous protein A production via a spa null muta-
tion. Bacteria were grown in Chelex-treated media to midlog
phase, a condition previously determined to induce cell-surface
expression of the MntABC transporter (Diep et al., 2014), and
then incubated with either FabC1 or an isotype control Fab
from the same phage library, followed by detection with labeled
secondary Fab. Under these conditions, approximately 8.3% of
the S. aureus cells bound FabC1 compared with <1.0% of cells
incubated with the isotype control Fab (Figure 1C). As expected,
<1.0% ofmntC null mutant cells bound FabC1, indicating spec-
ificity for MntC. Of note, when the cell wall barrier was weakened
by mutation of a critical techoic acid component (tagO), approx-
imately 89% of cells demonstrated binding to FabC1 (Figure 1C,
tagO series), likely due to increased access of FabC1 and sec-
ondary detection Fab to membrane-anchored MntC.
The ability of FabC1 to block MntC activity and thereby sensi-
tize bacteria to oxidative stress was next assessed. Wild-type
(WT) and mntC null mutant cells were incubated with an excess
of FabC1 or isotype control Fab, exposed to the ROS generator
methyl viologen (MV) and bacterial survival was assayed, similar
to what has been reported previously for mutants in the MntABC
pathway (Handke et al., 2013; Horsburgh et al., 2002a). As
shown in Figure 2A, WT pathogenic S. aureus (strain SF8300)
incubated with FabC1 displayed a >10-fold increase in sensi-
tivity to MV compared with cells exposed to isotype control
Fab, at the highest Fab concentration tested (100 mg/ml, i.e.
2 mM). The observed sensitivity to FabC1 increased to 46-
fold in the spa null background (Figure 2B), and the addition of
5 mM MnSO4 to the growth media was able to partially rescue
this phenotype (Figure 2C). These experiments used 66 mM
MV as an ROS generator; however, increased ROS sensitivity
in the presence of FabC1 was also observed for much lower
concentrations of MV, including down to 1 mM (Figure S1).reserved
Figure 2. FabC1 Sensitizes S. aureus to
ROS
(A–D) Effect of FabC1 on the sensitivity of (A) WT
S. aureus in the presence of 66 mM MV, (B) the
same strain in a spa null background, and (D)mntC
null mutant in the presence of 1 mM MV. A lower
MV concentration was used for the mntC null
mutant cells due to their extreme sensitivity to
ROS. (C) Partial rescue of FabC1 growth inhibition
by 5.0 mM Mn(II). Data shown are the average of
three independent experiments; error bars repre-
sent SD of the triplicate determinations.Conversely, no further increase in ROS sensitivity was observed
whenmntC null mutant bacteria were incubated in the presence
of FabC1 and 1 mM MV (a sublethal dose of MV for this strain,
which is hypersensitive to ROS due to the mntC null mutation),
indicating specificity of FabC1 for MntC (Figure 2D). Together
with the aforementioned binding studies, these results indicated
that although the cell wall is a barrier for full-length antibodies,
the smaller FabC1 could nevertheless access and antagonize
the MntABC pathway of WT pathogenic S. aureus by specifically
binding and blocking the activity of the MntC SBP.
Structure of the MntC-FabC1 Complex
To gain molecular insight into the mechanism of antagonism of
MntC by FabC1, we obtained a 2.7-A˚ crystal structure of the
MntC-FabC1 complex (Figure 3; Figure 4A; Table 1). We also ob-
tained a 1.17-A˚ crystal structure of isolated MntC bound to Zn(II)
(Figure S2A). Data collection statistics and refinement results are
summarized in Table 1. TheMntC-FabC1 complex crystallized in
the P21 space group with two MntC-FabC1 complexes in the
asymmetric unit. The structures of the two asymmetric unit com-
plexes superimposewith a root-mean-square deviation (rmsd) of
0.3 A˚. FabC1 has a typical Ig fold, aligning to the framework re-
gion of the humanized anti-p185HER2 antibody fragment from
which the phage display library was derived (Eigenbrot et al.,
1993). A closer look at the MntC-FabC1 interface reveals a
network of favorable interactions that stabilize the complex,
including hydrogen bond and salt bridge interactions, as detailed
in Table 2. These contacts are almost identical in the two asym-
metric unit complexes and bury a total solvent-exposed surface
area of 867 A˚2, with a larger contribution from the VH chain
(568 A˚2 versus 299 A˚2 from the VL chain). The FabC1 epitope
on MntC primarily encompasses residues on the a2 and a3 helix
of the C-terminal lobe, distal to the metal binding site (Figures 3
and 4B). The a3 helix of MntC binds in a groove created by the
complementarity-determining region (CDR) loops (L3, H2, andStructure 23, 713–723, April 7, 2015H3) of FabC1, whereas the a2 helix packs
against the CDR loop L3 of FabC1.
Our isolated Zn(II)-MntC structure is
essentially identical to the previously
published Mn(II)-bound structure (Gri-
benko et al., 2013), with an rmsd over
278 residues of 0.31 A˚. No obvious dif-
ference in the tetrahedral coordination
of the metal in the two structures is
observed, with an rmsd for the coordi-
nating residues of 0.10 A˚. The metalcontent of MntC in our structure was confirmed by inductively
coupled plasma-mass spectrometry (ICP-MS) analyses of the
crystallization sample (Table 3), as well as an X-ray fluores-
cence scan of the crystals (data not shown). Both analytical
methods indicated the protein was predominantly in the
Zn(II)-bound state. Moreover, comparison of the two-dimen-
sional 15N-1H transverse relaxation optimized spectroscopy
solution nuclear magnetic resonance (NMR) spectra of uni-
formly 15N-labeled Zn(II)-MntC (100% Zn(II) incorporation, Ta-
ble S1, sample 2a) and Mn(II)-MntC (>90%Mn(II) incorporation,
Table S1, sample 3a) obtained by refolding showed no obvious
difference in the secondary fold of the two metal-bound states
other than that attributed to the paramagnetic nature of the
Mn(II) ion (Figure S2B).
The structure ofS. aureusMntC in complexwith FabC1 closely
resembles the common metal binding fold found in related ABC
transporter SBPs, such as Streptococcus pneumoniae PsaA
(McDevitt et al., 2011), Cyanobacterium MntC (Rukhman et al.,
2005), and Zn(II)- and Fe(II)-binding homologs (Li and Jogl,
2007; Sun et al., 2009; Zheng et al., 2011) (Figure S3). This archi-
tecture is characterized by the presence of two 2-fold pseudo-
symmetrical lobes connected by a single linking a helix. The
N- and C-terminal lobes each comprise a four-stranded b sheet
with 2-1-3-4 linkages and intervening a helices ((b/a)4), with the
a helices packed against each face to form a tightly packed
metal/ligand coordination site (Gribenko et al., 2013; Jedrzejas,
2001). The conformation of MntC in the FabC1 complex is
also similar to the previously reported structure of isolated
S. aureus Mn(II)-MntC (Gribenko et al., 2013, PDB code 4K3V)
and our isolated Zn(II)-MntC structure, with an average rmsd of
0.68 A˚ over the backbone a carbons. However, there are notable
differences. In particular, we observed a large conformational
change in the a2-a3 helices of the C-terminal lobe of MntC that
involves the hydrophobic patch of residues Ile241, Ala262,
Met263, and Leu266. These residues are largely buried in theª2015 Elsevier Ltd All rights reserved 715
Figure 3. Crystal Structure of MntC-FabC1
Complex
A surface presentation of the crystal structure of
the complex between MntC (red) with FabC1
(blue). The CDR loops are highlighted in orange for
the VL chain and yellow for the VH chain of FabC1.
The inlay shows a zoomed in view of the interac-
tion interface between MntC and FabC1.isolated metal-bound MntC but are presented on the surface
of MntC in the complex structure and interact with residues,
primarily on CDR-L3, CDR-H2, and CDR-H3 of FabC1 (Table 2;
Figures 3 and 4B).
A second notable feature of the MntC-FabC1 complex
structure is that MntC has a solvent-exposed and empty metal
binding pocket, unlike the buried metal binding site in isolated
metal-bound MntC (Figure 4C; Figures S2C and S4). In the
FabC1 complex, no electron density for a metal ion is observed
where the coordinated metal ion would be expected (Figure 4D),
although there is weak density for a water molecule proximal to
the metal binding site. The primary metal coordinating residues
of MntC, namely His67, His140, Glu206, and Asp281, are also
shifted away from the metal coordination site in the complex
structure, as are some residues proximal to the coordination
site (Figures 4A inlay and 4D; Figure S3). Of note, fully Zn(II)-
and Mn(II)-loaded preparations of MntC were similarly placed
in crystal trials with FabC1; however, crystals could be obtained
only with recombinant MntC that was predominantly in the apo
state (Table S1, sample 1b).
Despite the observation of apo-MntC in the complex crystal
structure, extensive ICP-MS analyses indicated that FabC1
did not alter metal binding or release by MntC in vitro (Table
S1), nor did the presence of Zn(II) or Mn(II) ions significantly
alter the affinity of MntC for FabC1 in biolayer interferometry
binding experiments (Figure 1B). These results suggested
that the mechanism of inhibition by FabC1 was independent
of any allosteric effect on metal binding. The site of inter-
action of FabC1 on MntC instead pointed to a more likely
mechanism of inhibition of sterically blocking the interaction
of MntC with the MntB transporter. This hypothesis was
explored further.
Structural Comparison of SBP-Transporter Binding
and the MntC-FabC1 Complex
Despite generally low overall sequence identity, known SBPs
adopt a similar bilobed structure, with the substrate binding cleft
situated between the two N- and C-terminal lobes (Figure S2A).
The interaction interface between several SBPs and their trans-
porters has also been defined at the molecular level, and these
share common structural themes. For example, BtuF is the
SBP for the vitamin B12 transporter (Borths et al., 2002), and it716 Structure 23, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rights reservedundergoes key structural changes upon
interaction with its cognate transporter,
BtuCD (Borths et al., 2002; Hvorup
et al., 2007). In some ways, this SBP-
transporter binding is paralleled by the
interaction of MntCwith FabC1 (Figure 5).
For example, the C-terminal lobe regionof MntC that interacts with FabC1 is the same face of BtuF
that forms part of the interaction with the BtuCD transporter.
FabC1 is positioned to sterically block this face, in the likely
event that this region of MntC interacts with MntB during ion
import. The MntC-FabC1 complex structure also reveals a
conformational change in MntC that results in an 4-A˚ separa-
tion of the a2 and a3 helices of the C-terminal lobe away from
the metal coordination site, thereby exposing the latter to sol-
vent. This open conformation is similar to that of BtuF upon
transporter binding and substrate release (Hvorup et al., 2007)
(Figure 5A), as well as the open conformations of related metal
binding SBPs, including PsaA (Figure S4) (Counago et al.,
2013; Quiocho and Ledvina, 1996).
Structural parallels can also be made with the Escherichia coli
maltose transporter. High-resolution crystal structures of the
maltose transporter complex trapped in different stages of the
transport cycle (Oldham and Chen, 2011a, 2011b; Oldham
et al., 2007, 2013), aswell as extensive site-directed spin labeling
and electron paramagnetic resonance spectroscopy studies
(Austermuhle et al., 2004; Cui et al., 2010), have extensively char-
acterized the conformational changes that the maltose binding
protein (MBP) SBP undergoes upon binding maltose and its
cognate transporter, MalFGK2. MBP adopts a closed conforma-
tion upon binding maltose, whereby the N- and C-terminal lobes
come together to form the substrate binding site. Although the
extent of N- and C-terminal lobe closure around substrate is
considerably less for Zn(II)-MntC (as is typical for related metal
ion binding SBPs), the metal-ion coordinating residues are
contributed by both the N- and C-terminal lobes of MntC, and
these nevertheless do come together in the closed conformation
(Figure 5B). Upon binding theMalFGK2 transporter, MBP adopts
an open conformation, which facilitates release of maltose to the
transporter. This is accompanied by a 7.0- to 9.0-A˚ separation of
both the N- and C-terminal lobes of MBP away from the maltose
binding site. Both the N- and C-terminal lobes of MBP engage
the transporter during the transport cycle, in contrast to the
apo-MntC/FabC1 complex, in which only movement of the
C-terminal lobe away from the metal coordination site is
observed. As with BtuF, the face of the C-terminal lobe of MBP
that contacts the membrane transporter is similar to the struc-
tural region of MntC that is blocked by FabC1 (Oldham and
Chen, 2011a).
Figure 4. MntC Showcases an Empty Metal Binding Site in Complex with FabC1
(A) Overlay of crystal structure of MntC alone bound to Zn(II) (blue, with Zn(II) as a black sphere) with the crystal structure of apo-MntC (pink) bound to FabC1 (gray
surface). The inlay shows a closer view of themetal binding site, highlighting the rearrangement of the primary metal coordinating residues in apo-MntC (in FabC1
complex), compared with Zn(II)-MntC.
(B) View of interaction surface between apo-MntC and FabC1, highlighting the hydrophobic patch of residues on a2 and a3 of the C-terminal lobe that are largely
buried in the interior of the lobe in Zn(II)-MntC (blue) but are rearranged in apo-MntC (pink) to interact with FabC1 in the complex structure.
(C) Surface representation of Zn(II)-MntC (blue) and apo-MntC (pink) in stereo view, highlighting a closed metal binding pocket compared with the solvent-
exposed, open metal binding pocket in apo-MntC. The metal ion is represented as a yellow sphere but is not present in apo-MntC of the FabC1 complex.
(D) Metal binding pocket of MntC in the FabC1 complex structure (pink), highlighting the 2Fo  Fc map of electron density contoured to 1.0 s (grid). For com-
parison, the structure of the isolated Zn(II)-MntC metal coordination site is shown in light gray (with Zn(II) as a gray sphere). See also Figure S2.FabC1 Blocks the Interaction of MntC with the MntB
Transporter
Based on the structural analyses, we reasoned that FabC1 in-
hibits the MntABC transporter by sterically blocking a surface
of MntC that normally interacts with MntB during metal import.
Efforts to test the ability of FabC1 to block the interaction of
MntC with MntB in direct competition binding studies failed
because we were unable to produce functional MntB or an
MntAB complex, despite extensive efforts with theS. aureus pro-
teins and homologs from several other bacterial species. Instead,
we examined if mutations in the FabC1 epitope on MntC could
mimic the ROS sensitivity of an mntC null mutant of S. aureus
(Handke et al., 2013; Horsburgh et al., 2002a), as would be ex-
pected if the epitope overlapped with the MntB interaction site.
Three MntC mutants were generated, probing residues at theStructure 23interface between the C-terminal lobe of MntC and FabC1 (Fig-
ure 6A). SEC analyses with FabC1 indicated that the purified
mutant proteins were monodisperse; however, all had a reduced
affinity for FabC1, as shownby a significant reduction in the com-
plex resolved (Figures 6B–6E). Biolayer interferometry (Octet)
analyses were carried out to determine mutant binding affinities
for FabC1. Mutant A (K230A, T233A) showed an 3- to 4-fold
decrease in binding affinity to FabC1 (KD = 420± 67 nM),whereas
mutants B (E235A, M237A) and C (R238A) did not exhibit any
detectable binding, consistent with the SEC results. The metal
contents of the threemutants were similar toWTMntC produced
under the same conditions, indicating that these mutations did
not allosterically perturb metal binding (Table 3).
All three MntC mutants expressed to levels similar to WT pro-
tein in anmntC null S. aureus strain (Figure 7A). The sensitivity of, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 717
Table 1. Crystallographic Data Reduction and Refinement
Statistics for S. aureus MntC Alone and in Complex with FabC1
MntC + Zn2+ MntC-Fab Complex
Data Collection
Space group P212121 P21
Cell dimensions
a, b, c (A˚) 54.57, 63.44, 69.60 100.1, 92.5, 127.9
a, b, g () 90, 90, 90 90, 92.5, 90
Resolution range (A˚) 35.56–1.17 (1.26–1.17)a 50.00–2.7 (2.8–2.7)
Rsym (%) 5.5 (29.2) 14.6 (52.8)
hIi=hsIi 31.76 (5.57) 9.5 (2.2)
Completeness (%) 98.4 (87) 89.7 (90.2)
Redundancy 6.3 (6.0) 2.5 (2.5)
Refinement




Rwork/Rfree (%) 15.0/16.0 22.4/28.3









Bond lengths (A˚) 0.009 0.01
Bond angles () 1.089 1.39
Ramachandran
Favored (%) 96.6 93.5
Allowed (%) 3.4 6.2
Outliers (%) 0.0 0.3
aAll values in parentheses are for the highest-resolution shell.
Table 2. Hydrogen Bond and Salt Bridge Interactions between
MntC and FabC1
Residue Atom Residue Atom Distance (A˚)
MntC FabC1 (VH)
Arg238 NE Tyr52 OH 3.0
Glu235 OE2 Ser55 N 2.5
Glu235 OE2 Ser55 OG 2.4
Lys230 NZ Tyr108 OH 3.8
Gly232 O Tyr109 N 2.8
Arg238a NE Glu113 OE1 3.0
Arg238a NH2 Glu113 OE1 3.4
Arg238a NE Glu113 OE2 2.9
Arg238a NH2 Glu113 OE2 3.0
MntC FabC1 (VL)
Arg238 NH1 Ser95 O 2.7
Arg238 NH2 Ser91 O 3.2
aSalt bridge interactions.these mutants to MV was assessed using the aforementioned
ROS survival assay. As shown in Figure 7B, themntC null mutant
carrying an empty plasmid demonstrated a 20-fold decrease in
survival relative to the WT strain, whereas the mntC null mutant
carrying a complementing plasmid expressing theWTMntC pro-
tein demonstrated survival within 3-fold of the parental WT
strain. However, none of themntC point mutants rescued growth
toWT levels. In particular, the single R238Amutation in mutant C
resulted in MV sensitivity indistinguishable from the mntC null
mutant. These results were consistent with the hypothesis that
blocking this site with FabC1 prevented the interaction of MntC
with MntB, rendering S. aureus defective in Mn(II) import and
consequently hypersensitive to ROS.
DISCUSSION
The goal of this study was to explore the feasibility of directly in-
hibiting a bacterial ABC importer with an antibody fragment that
targets its SBP and to provide a detailedmolecular description of718 Structure 23, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rightsthe mechanism of inhibition. Of the many ABC import pathways
in S. aureus, the MntABC pathway is a particularly promising
antibacterial target, because metal homeostasis plays a critical
role in virulence andMn(II) import is essential for defense against
oxidative stress (Handke et al., 2013; Kehl-Fie et al., 2013). Also,
all components of the MntABC pathway are essential for methi-
cillin-resistant S. aureus virulence in a murine systemic infection
model (Diep et al., 2014) and are highly expressed during infec-
tion (Anderson et al., 2012b). In a recent study by den Reijer et al.
(2013), patients infected with S. aureus showed an increase in
IgG antibody titer against MntC that exceeded that of any other
protein antigen examined, indicating that the MntC SBP is
accessible to the host immune system and among the most
immunologically recognized antigens of S. aureus. In agreement
with this, the expression of MntC can be detected on the surface
of diverse S. aureus strains when examined by whole-cell ELISA
of clinical isolates (Handke et al., 2013) or immunofluorescence
staining of bacteria taken directly from murine wound infection
and bacteremia models (Timofeyeva et al., 2014). But, despite
its role in infection, no specific inhibitors of MntC or other com-
ponents of the MntABC pathway are known.
Although some current antibacterial development strategies
are aimed at targeting bacterial ABC importers, to our knowl-
edge no clinically useful inhibitors of these pathways are yet
available. For example, immunization of mice with purified ABC
importer SBPs such as PiuA, PiaA, and PsaA of S. pneumoniae
(Briles et al., 2000; Brown et al., 2001) or MntC from S. aureus
(Anderson et al., 2012a, 2012b; Brady et al., 2006) can elicit
some protective immunity in mice; however, it has not been
determined if the antibodies generated can directly block ABC
importer activity. Rather, the logic behind this approach is that
these targets may be suitable candidates for multiantigen vac-
cines. A very different preclinical strategy exploits the broad
specificity of some peptide ABC importers to facilitate the up-
take of antibacterial drugs that are covalently linked to natural
transporter substrates (Marshall et al., 2003). This approach is
likewise not founded on ABC transporter inhibition. In the pre-
sent case, we investigated the use of an engineered antibodyreserved
Table 3. ICP-MS Analyses of Metal Ion Binding to Purified
Mutants of MntC
MntC Sample 66Zn (%) 55Mn (%)
Other Divalents Including
60Ni, 59Co, and Trace
Amounts of Fe and Cu (%)
WT 80.2 ± 2.9 13.1 ± 5.9 6.7 ± 2.9
Mutant A
(K230A, T233A)
79.5 ± 0.1 15.8 ± 0.1 4.7 ± 0.1
Mutant B
(E235A, M237A)
80.3 ± 0.1 15.7 ± 0.2 4.0 ± 0.1
Mutant C
(R238A)
92.2 ± 0.1 7.8 ± 0.1 0.0
All errors reported are the SD from the mean of three independent
experiments.fragment to specifically inhibit the SBP of an S. aureus ABC
import pathway that is essential for metal homeostasis. This
proved to be a fruitful approach, since the single Fab isolated
by phage display not only bound the MntC SBP on the surface
of S. aureus but also sensitized bacteria to oxidative stress, a
hallmark of defective Mn(II) import. Under our experimental con-
ditions, the import of Mn(II) through the only other known Mn(II)
importer in S. aureus, MntH (Diep et al., 2014; Handke et al.,
2013; Horsburgh et al., 2002a), was apparently insufficient to
compensate for the loss of MntABC activity. This is consistent
with the observation that all components of the MntABC
pathway are essential during infection in vivo (Diep et al., 2014).
Our functional and structural analyses of the MntC-FabC1
complex indicate that FabC1 inhibits the MntABC pathway by
blocking the interaction of the extracytoplasmic MntC (SBP)
with the MntB importer. Two fundamental observations support
this conclusion. First, interpretation of our complex structure
with regards to high-resolution structural data for other ABC
transporters, like BtuCDF (Borths et al., 2002; Hvorup et al.,
2007) and the MBP- MalFGK2 maltose transporter (Oldham
and Chen, 2011a, 2011b; Oldham et al., 2007, 2013), indicates
that FabC1 sterically blocks a region of MntC that is expected
to interact with the MntB transporter (Figure 5B). A prediction
of this model is that mutation of the FabC1 epitope on MntC
should sensitize S. aureus to oxidative stress, and this was
observed (Figure 7). Second, MntC undergoes a structural rear-
rangement when bound to FabC1 that exposes its metal coordi-
nation site to solvent. This open conformation of apo-MntC is
similar to that of other SBPs when bound to their cognate trans-
porters (Borths et al., 2002; Hvorup et al., 2007), as well as theStructure 23apo states of related metal binding SBPs (Figure S4). While
FabC1 does not prevent metal binding by MntC in vitro
(Table S1), it nevertheless appears to shift the equilibrium of
MntC towards an open conformation, as observed in the crystal
structure. The same must occur when MntC is bound to MntB
during the Mn(II) import cycle, since directed movement of resi-
dues in and around the metal coordination site would be neces-
sary for Mn(II) release to the MntB permease.
We found that by blocking MntC activity, FabC1 was able to
significantly inhibit the growth of WT S. aureus under ROS-
generating conditions designed to mimic the oxidative host envi-
ronment. Further, our whole-cell binding studies (Figure 1C) and
ROS phenotypic assays (Figure 2) clearly indicated that a Fab
fragment can access and inhibit an extracytoplasmic target,
like MntC, even in WT pathogenic S. aureus. Given the strong
ROS sensitivity phenotype in the presence of FabC1, we suspect
that the observation that only 8.3% of cells bound FabC1 by
fluorescence-activated cell sorting (FACS) was an underesti-
mate, because detection of a positive signal required that both
FabC1 and secondary detection Fab access and remain bound
to MntC, over the course of many washes. In this respect, it is
also worth noting that S. aureus protein A binds with high affinity
to the Fc region of full-length antibodies and has weaker affinity
for the Fab fragments of VH3 antibodies, which lack the Fc
domain (An, 2009; Hillson et al., 1993). However, FabC1 is not
a suitable antimicrobial drug in its current form. We did not
perform affinity maturation of FabC1 for these studies; the
measured FabC1 affinity for MntC was >100 nM. Future efforts
will examine if variants of FabC1 with improved affinity for
MntC and mutations that eliminate all protein A binding (Graille
et al., 2000) further increase S. aureus sensitivity to ROS and
are efficacious in vivo. Also, the in vivo half-lives of Fab frag-
ments are shorter than those of full-length antibodies (Spiegel-
berg and Weigle, 1965) and this may limit their clinical use. We
are currently assessing the in vitro and in vivo activities of alter-
native antibody formats in which the antigen-binding region of
FabC1 is transferred to surrogate scaffolds, including single-
chain fragment variable (scFv), nanobody, and monomeric vari-
able domains. Such antibody fragment therapeutics may poten-
tially broaden the repertoire of strategies that can be used to
combat pathogenic gram-positive infections. The observation
that patients infected with S. aureus are known to produce
high antibody titers against MntC (den Reijer et al., 2013) sug-
gests that MntC is accessible and that this could be a productive
strategy, as might other variants of FabC1 (Mould and Sweeney,
2007). Our functional and structural work on MntC and FabC1Figure 5. Comparison of MntC with Struc-
turally Related SBPs
(A) Overlay of BtuF alone bound to vitamin B12
(cyan-blue) and apo-BtuF (gray) bound to BtuCD
(gold), highlighting the interaction surfaces of BtuF
and the BtuCD transporter.
(B) Zn(II)-MntC (blue) and apo-MntC (pink), high-
lighting the interaction surface of MntC with
FabC1 (pink surface) and a rearrangement and
separation of the C-terminal lobe away from the
ligand pocket upon loss of the substrate/ligand.
See also Figure S3.
, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 719
Figure 6. Biochemical Characterization of
MntC Mutants
(A) Surface representation of apo-MntC, high-
lighting residues in the interface with the VH chain
(cyan-blue) and VL chain (yellow) of FabC1.
(B) Overlay of sizing profiles of isolated MntC (blue
trace) and FabC1 (red trace). Note the late elution
of FabC1, indicative of nonspecific interaction with
the column resin.
(C–E) Sizing profiles and SDS-PAGE gels of the
MntC mutants. All MntC mutant proteins were
monodisperse; however, MntC-FabC1 complex
was not observed for mutants B–D. The FabC1 KD
for mutant A is shown on the SEC trace and was
determined by biolayer interferometry. Data
shown are the average of three independent
experiments; error is the SD of the triplicate de-
terminations. KD could not be determined for
mutants B and C (n.d.).therefore serves as a basis for targeting prokaryotic ABC trans-
port pathways with engineered antibody or peptide therapeutics
that block one of the first critical steps in the transport pathway,
namely transfer of substrate by the surface-associated SBP to
the membrane importer.
EXPERIMENTAL PROCEDURES
Recombinant Production of WT MntC
An inducible expression construct for soluble MntC (Gly19-Lys309) from
S. aureus containing an amino terminal octahistidine tag and TEV protease
cleavage site was cloned into the pET11a vector (EMD Millipore) and trans-
formed into E. coli BL21 Gold (DE3) cells (Agilent). Cells were grown in Luria
broth (LB) at 37C to an OD600 of 1.0. MntC expression was then induced
with 0.4 mM isopropyl b-D-1-thiogalactopyranoside and the cultures grown
for an additional 24 hr at 16C. Cell pellets were harvested by centrifugation
at 20,000 3 g for 20 min at 4C. For generation of the MntC sample used for
the FabC1 complex crystallization, cells were grown under the same condi-
tions in minimal (M9) media. This was done to minimize the incorporation of
Zn(II) into the MntC metal coordination site. Isotopically labeled (uniformly
15N) MntC samples for NMR analyses were grown as above, however, in min-720 Structure 23, 713–723, April 7, 2015 ª2015 Elsevier Ltd All rights reservedimal (M9) media supplemented with 15NH4Cl (1 g/l)
(Cambridge Isotope Laboratories) and U-15N
labeled ISOGRO (1 g/l) (Isotech) for U-15N MntC.
All subsequent purification steps were per-
formed at 4C. 5.0 g of cell paste was resus-
pended in 100 ml of lysis buffer (300 mM NaCl,
10% glycerol, 25 mM HEPES [pH 7.5]) containing
one complete EDTA-free Protease Inhibitor Cock-
tail tablet (Roche) per 50ml of buffer. Lysates were
generated by passage of cells through a micro-
fluidizer at 15,000 psi and clarified by centri-
fugation at 50,000 3 g for 1 hr. 0.22 mm filtered
supernatant was resolved on either a 5-ml HiTrap
Talon or HisTrap HP affinity column (GE Health-
care), washed with lysis buffer containing 15–
20 mM imidazole and eluted with an 80-ml linear
gradient from 15 to 500 mM imidazole.
The affinity tag was removed by the addition of
TEV protease. MntC was then resolved on an
S75 16/60 gel filtration column (GEHealthcare) us-
ing PBS (pH 7.2) as the running buffer. Fractions
containing >95% pure, monodisperse MntC
were pooled, concentrated to 13 mg/ml, andused immediately in crystal trials or complex formation with FabC1 or stored
at –80C.
Cloning and Expression of MntC Mutants
Mutants of MntC were generated as alanine substitutions by QuikChange II XL
site-directed mutagenesis (Agilent). Mutant A was K230A/T233A, mutant B
was E235A/M237A, and mutant C was R238A. All MntC mutants were ex-
pressed and purified as detailed for WT soluble MntC.
FabC1 Isolation and Production
An anti-MntC antibody fragment (FabC1) was generated using phage display
methodology as detailed previously (Fellouse et al., 2007; Tonikian et al.,
2007). Briefly, a human synthetic, minimalist Fab library (library D) with diver-
sities in the H1, H2, H3, and L3 regions was used for selection (Fellouse
et al., 2007). The library was cycled through rounds of binding selection using
a standard plate sorting protocol (Tonikian et al., 2007). 20 mg/ml of MntC
treated with 20 mM EDTA was coated on 96-well MaxiSorp immunoplates
as the capture target. After four rounds of binding selection, individual phage
clones were picked, propagated, and analyzed by phage ELISA. Positive
clones were sequenced and unique clones selected for further manipulation.
A stop codon was inserted between the Fab sequences and theM13 coat pro-
tein P3 to generate constructs suitable for periplasmic expression of Fab in
Figure 7. FabC1 Blocks the MntB Interaction Interface on MntC
(A) Western blot using rabbit polyclonal sera raised against purified MntC,
indicating that all four MntC mutants express to levels similar to WT protein in
an mntC null S. aureus strain.
(B) Effect of point mutations in MntC on the survival of S. aureus under ROS-
generating conditions. Data shown are the average of three independent ex-
periments and error bars represent SD of the triplicate determinations.
Mutated residues are indicated in the text.E. coli. The plasmid encoding FabC1 was transformed into 34B8 E. coli cells
and expressed at 30C under control of the phoA promoter in CRAP phos-
phate-limiting autoinduction medium (Simmons et al., 2002) supplemented
with carbenicillin (50 mg/ml). After 24 hr, cells were harvested and resuspended
in PBS supplemented with one complete EDTA-free Protease Inhibitor
Cocktail tablet (Roche) per 50 ml of lysis buffer, lysozyme (0.1 mg/ml), and
benzonase (0.01 mg/ml). The prepared suspension was microfluidized at
15,000 psi and clarified at 50,000 3 g for 30 min at 4C. The supernatant
was then resolved on protein G Sepharose beads equilibrated with PBS, using
2 ml packed resin volume per original gram of cell paste. The column was
washed extensively with PBS and FabC1 was eluted under mildly acidic con-
ditions (0.56 % glacial acetic acid [pH 3.6]). Eluted FabC1 was immediately
dialyzed overnight at 4C against buffer containing 500 mM NaCl, 10% glyc-
erol, and 100 mM Tris (pH 8.0). FabC1 was further resolved on an S75 16/60
gel filtration column (GE Healthcare) using PBS (pH 7.2) as the running buffer.
Isolated FabC1 had a higher than expected retention volume on the column,
indicating some nonspecific interaction with the S75 resin (Figure 6B).
MntC-FabC1 Binding Assays
Binding of FabC1 to purifiedMntCwasmeasured using biolayer interferometry
on an Octet RED384 instrument (ForteBio). Subequimolar EZ-Link sulfo-NHS-
biotin (Thermo Fisher Scientific) was used to biotinylateMntC and this was car-
ried out at room temperature for 2–3 hr, followed by dialysis overnight against
buffer A (25 mMHEPES, 100 mMNaCl [pH 7.5]) at 4C. BiotinylatedMntC was
captured on streptavidin SA biosensors at 10 mg/ml andwashed to remove any
unbound material before conducting measurements with FabC1 in Buffer A
supplemented with 0.1 mg/ml BSA and 0.05% Tween 20. The buffer wasStructure 23also supplemented with 1 mM MnCl2 for the experiments with Mn(II)-MntC.
The interactions displayed rapid saturation behavior. The kinetic data were
fit to a simple 1:1 binding model to determine the affinity constant (KD) using
the association (Kon) and dissociation (Koff) rates. For MntC-mutant A, kinetic
data did not fit well to the binding model due to a relatively large proportion
of nonspecific binding (data not shown). For this mutant, the calculation was
made using estimated response at equilibrium for each analyzed concentra-
tion. Binding assays were performed in triplicate and average KD values re-
ported with SDs.
S. aureus FACS and ROS Survival Assays
Additional details on the protocols for the FACS analysis and ROS survival
assay are included in the Supplemental Information. Briefly, FACS and ROS
studies were performed using themethicillin-resistant SF8300S. aureus strain,
with appropriate mutations and/or complementation vector introduced as
described in the text. For FACS studies, all strains were spa null to minimize
nonspecific binding of antibody. Bacteria were immunolabeled with FabC1
or isotype control Fab followed by labeling with secondary detection Fab.
Binding was then monitored by flow cytometry. For the ROS survival assay,
log phase cells were grown in the presence of FabC1, isotype control Fab,
or an equivalent volume of buffer. For rescue experiments, 5 mM MnSO4
was added. Cells were then grown overnight in the presence of the ROS gener-
ator MV and the surviving colony-forming units determined by serial dilution.
Structure Analyses
Additional details on the X-ray crystallography and NMR structure studies are
provided in the Supplemental Information. In summary, purified Zn(II)-MntC
and MntC-FabC1 complex were crystallized by vapor diffusion. X-Ray diffrac-
tion data of 1.17 A˚ and 2.7 A˚ resolution, respectively, were collected and struc-
tures determined by molecular replacement. For NMR studies, uniformly
15N-labeled Mn(II)-MntC and Zn(II)-MntC were generated as described earlier
and in the Supplemental Information. The metal content of these samples was
confirmed by ICP-MS (see below). Spectra were recorded at 298 K on a Bruker
Avance 600 MHz or 900 MHz NMR system equipped with a cryoprobe.
MntC Refolding and ICP-MS Analyses
Zn(II)-bound MntC was produced by incubating the purified protein with
excess Zn(II). Generation of Mn(II)-bound and apo forms of MntC required
denaturation and refolding, essentially as described previously (Lim et al.,
2008). The metal content of all samples was thoroughly characterized by
ICP-MS analyses. Additional details are provided in the Supplemental
Information.
ACCESSION NUMBERS
Structure coordinates have been deposited in the PDB database with the
accession numbers 4NNO (Zn(II)-MntC) and 4NNP (MntC-FabC1 complex).
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